TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics
Brief Summary: The purpose of the ALL Study is to determine the effectiveness of the dissemination of the ALL intervention from an integrated care setting into Community Health Centers (CHCs) by measuring changes in diabetes mellitus (DM) population prescription rates for the medications, using a pre-post comparison within clinics and a staggered, randomized implementation across clinics.


Options:
A: Inclusion Criteria:

* African American veteran
* 50-70 years old
* ICD-9CM diagnosis code consistent with DM (any ICD-9CM code starting with 250)
* For patients: last two HbA1c greater than 8% with at least one measure being within 3 months of enrollment
* For peer counselors: HbA1c of greater than 8% in the past 3 years and an HbA1c less than or equal to 7.5% within 3 months of enrollment

Exclusion Criteria:

* Unstable medical condition that would likely prevent the subject from completing the study
* Patients enrolled in Telehealth will be excluded as such enrollment does not constitute usual care
B: Inclusion Criteria:

* Diagnosis of diabetes mellitus (based on fasting glucose, HbA1c, and problem list)
* At least 18 years old
* At least one face-to-face visit with Harvard Vanguard primary care clinician in the last 2 years

Exclusion Criteria:

* Any patient not categorized as either White or Black based on race identifier in the electronic medical record
C: Inclusion:

* Commercially-insured beneficiaries
* Receive all medical/prescription drug benefits through Horizon
* On ≥1 one oral hypoglycemic agent
* Latest HbA1c measurement ≥ 8% (within previous 6 months)
* Provided phone number to Horizon

Exclusion:

- Currently using any insulin
D: Inclusion Criteria:

* Convenience sample of 11 community health clinics (CHCs) that are members of OCHIN, Inc.

Exclusion Criteria:

* none, for study CHCs

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Functional and Cognitive Impairment Prevention Through Early Physical Activity for Elderly Hospitalized Patients: a Randomized Clinical Trial
Brief Summary: The current model of care for the hospitalized elderly patients has been conditioned by many factors unrelated to the disease process that caused the hospitalization and usually worsen the outcome of hospitalization circumstances. Many times hospitalized elderly patients spend most of the time in bed (even higher than 83% of bed rest versus 4% of those who stand or are walking). These patients have their functional and physiological reserve reduced which makes them more vulnerable to the effects of being bedridden. The consequences are at multiple levels emphasizing the functional loss or cognitive impairment, longer stays, mortality and institutionalization, delirium, deconditioning, pressure ulcers and decreased caloric intake, social isolation, poor quality of life and increased use of resources related to health. Exercise training can prevent functional and cognitive decline and modify even the posterior trajectory.


Options:
A: Inclusion Criteria:

• Eligible patients will be admitted acutely for a femoral neck fracture, a trochanteric or a subtrochanteric femoral fracture.

Exclusion Criteria:

* Hip fracture as part of multi-trauma or high energy trauma (defined as a fall from a higher level than 1 metre). One recent fracture in addition to the hip fracture (e.g. radius or shoulder) is acceptable.
* Regarded as moribund at admittance.
* Absence of a valid informed consent or assent.
B: Inclusion Criteria:

* 70+ years
* minimum hospital stay of 5 days
* living at home
* positive cognitive screening (MMSE)
* written informed consent

Exclusion Criteria:

* stroke
C: Inclusion Criteria:

* On a daily basis during the study period (weekdays from 7am to 5pm), each operating room of Barnes-Jewish Hospital (BJH) will be eligible for randomization, which will occur at the level of the operating room using computer-generated assignment.

Exclusion Criteria:

-
D: Inclusion Criteria:

* Age 75 years and older
* Able to tolerate exercise
* Able to ambulate, with or without personal / technical assistance or move unassisted in a wheelchair
* Able to communicate
* Non-elective admission to hospital

Exclusion Criteria:

* Severe dementia (GDS 7)
* Duration of hospitalization \<72 hours
* Unwillingness to either complete the study requirements or to be randomized into control or intervention group
* Unstable cardiovascular disease or other unstable medical condition
* Terminal illness

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Automatic Oxygen Administration in Spontaneous Ventilation During the Hypoxemic Acute Respiratory Distress in Infants and Children
Brief Summary: The aim of the study is to assess the use feasibility of the FreeO2 system so as to deliver automatically oxygen in infants and children admitted at hospital for hypoxemic acute respiratory distress.

In healthy volunteers adults, FreeO2 system provided a better control of the oxygen saturation in function of designed target, reducing the desaturation time and hyperoxia. Our hypothesis is that FreeO2 system use is feasible in infants and children with hypoxemic acute respiratory distress. We think FreeO2 will provide a better control of the oxygen saturation, a faster oxygen weaning than classical way (Rotameter). In addition, FreeO2 could reduce the number of intervention by nurses.


Options:
A: Inclusion Criteria:

* Admission to the emergency for respiratory disease justifying an oxygen administration to maintain a SpO2 ≥ 92%.
* inclusion within a time less than 24 hours after the start of the oxygen at the emergency department.
* written consent of the parents of the child

Exclusion Criteria:

* Necessity of an oxygen flow exceeds 4 L / min to maintain a SpO2 higher than 92%
* Criteria of gravity justifying immediately a different technique of ventilatory support:

  * Disturbance of consciousness with a Glasgow Coma Score ≤ 12
  * Hemodynamic instability (MBP \< - 2 DS or need for vasopressors)
  * Cardiac or respiratory arrest
  * pH \< 7.35 and PaCO2 \> 55 mm Hg
  * Necessity of a urgent surgery
  * Age \< 1 month
  * Respiratory rate \> 80 b/min (1 month-2 years old), \> 40 b/min (2 - 10 years old) \> 30b/min (\> 10 years old) ou \< 10 b/min
B: Inclusion Criteria:

* birthweight 500 to 1250 grams
* postnatal age day 1 to day 10
* infant considered a candidate for methylxanthine therapy by clinical staff

Exclusion Criteria:

* dysmorphic features or congenital malformations that adversely affect life expectancy or neurodevelopment
* unlikely to comply with long-term follow-up
* prior treatment with a methylxanthine
C: Inclusion Criteria:

* Preterm infants less than 31 weeks completed gestation at birth requiring mechanical ventilation and admitted to King's NICU in the first 48 hours after birth

Exclusion Criteria:

* Preterm infants above 31 weeks completed gestation or term born infants
* Infants with major congenital abnormalities
D: Inclusion Criteria:

Preterm infants less than 33 weeks (23+0 to 32+6 weeks)

• Receiving invasive or non-invasive mode of respiratory support

Exclusion Criteria:

* Infants more than or equal to 33 weeks
* Preterm infants with congenital anomalies
* Infants on a non-conventional mode of invasive or non-invasive ventilation

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial
Brief Summary: The purpose of this study is to assess whether the administration of a low dose of tranexamic acid just after vaginal delivery can reduce the incidence of immediate postpartum hemorrhage, in women who receive a prophylactic administration of oxytocin.


Options:
A: Inclusion Criteria:

* Women\>18 years,
* during first stage of normal labor,
* at 36 to 42 weeks,
* with epidural analgesia and informed signed consent

Exclusion Criteria:

* Cesarean section delivery,
* clotting disorders,
* prostaglandin allergy,
* absent consent.
B: Inclusion Criteria:

* Women who have given birth to 1 or more live-born infants (para 1 or more)
* Vaginal delivery

Exclusion Criteria:

* Refusal or inability to give informed consent
* Delivery regarded as abortion according to local gestational age limits
* Inability to take misoprostol sublingually
* Cesarean section
* Assisted vaginal delivery
C: Inclusion Criteria:

* gestational age between 37 and 42 weeks,
* live fetus,
* cephalic presentation,
* vaginal birth.
* Patients who had a risk factors for PPH, such as multiple gestation, polyhydramnios, fetal macrosomia, antepartum hemorrhage, anemia (haemoglobin concentration \< 8 g/dL), severe pre-eclampsia, or coagulopathy

Exclusion Criteria:

* placenta previa,
* placental abruption,
* cesarean section or any uterine scar, abnormal placentation (accreta, increta, or percreta),
* a current or previous history of significant disease, including heart disease, liver, renal disorders.
D: Inclusion Criteria:

* Age≥ 18 years
* Planned vaginal delivery
* Term ≥ 35 weeks of gestation
* Singleton pregnancy
* Informed consent form signed

Exclusion Criteria:

* History of venous (deep vein thrombosis and/or pulmonary embolism) or arterial (angina pectoris, myocardial infarction, stroke) thrombosis.
* History of epilepsy or seizure
* Any known cardiovascular, renal, liver disorders
* Auto-immune disease
* Sickle cell disease
* Severe hemorrhagic disease
* Placenta previa
* Abnormally invasive placenta (placenta accreta/increta/percreta)
* Abruptio placentae
* Eclampsia; hemolysis, elevated liver enzymes, low platelet count (HELLP) syndrome
* Multiple pregnancy
* In utero foetal death
* Administration of Low-Molecular-Weight Heparin or antiplatelet agents seven days before delivery
* Poor understanding of the French language

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial
Brief Summary: 200 women will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland).


Options:
A: Inclusion Criteria:

1. delivering at home or sub-center with an auxilliary nurse midwife (ANM)
2. able and willing to provide informed consent
3. meeting Ministry of Health Guidelines for home or sub-center delivery

Exclusion Criteria:

1. high-risk pregnancy
B: Inclusion Criteria:

* Vaginal delivery
* Postpartum hemorrhage due to suspected uterine atony
* Depending on study group: administration of prophylactic uterotonics in third stage of labor

Exclusion Criteria:

* Known allergy to misoprostol or other prostaglandin
* C-section for current delivery
C: Inclusion Criteria:

* Women with atonic PPH.

Exclusion Criteria:

* Gestational age \<37 weeks.
* Hypertension.
* Preeclampsia.
* Cardiac, renal or liver diseases
* Epilepsy.
* Known hypersensitivity to Carbetocin
D: Inclusion Criteria:

* Women with atonic PPH.

Exclusion Criteria:

* Gestational age \<37 weeks.
* Hypertension.
* Preeclampsia.
* Cardiac, renal or liver diseases
* Epilepsy.
* Known hypersensitivity to Carbetocin

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health
Brief Summary: The purpose of this study to assess the effect of maternal vitamin D3 (cholecalciferol) supplementation on maternal HIV progression, small-for-gestational age infants, and infant stunting at 12 months postpartum for HIV-infected Tanzanian pregnant women who are receiving highly active antiretroviral therapy (HAART).


Options:
A: Inclusion Criteria:

* 13-19 y old
* between 23 and 29 wk of gestation
* primiparous
* carrying single fetus
* intending to exclusively or predominantly breastfeed

Exclusion Criteria:

* chronic health problems
* smokers
* users of nutritional supplements, except iron supplements provided during standard prenatal care
B: Inclusion Criteria:

* Women aged ≥18 years old
* HIV-positive
* Receiving HAART
* Pregnant and of 12-27 weeks gestation (Second Trimester)
* Calcium levels in the normal physiologic range (≤2.6 mmol/L)

Exclusion Criteria:

* Enrolled in any other clinical trial
C: Inclusion Criteria:

* Pregnant women attending antenatal clinic at ≤ 20 weeks of gestation
* Normoglycemic, normotensive at the time of antenatal booking

Exclusion Criteria:

* Multiple pregnancy
* H/O hypertensive disorders in previous pregnancy
* Known diabetic or h/o gestational diabetes in previous pregnancy
* H/O endocrine disorders ( thyroid, parathyroid dysfunction)
* Chronic renal diseases
* Tuberculosis
* Breast feeding (current)
D: Inclusion Criteria:

* Adult (\>18 years)
* No more than 18 weeks gestation
* In good general health
* Low risk pregnancy
* Not consuming \>10 mcg/d vitamin D from supplements

Exclusion Criteria:

* Current smokers
* Diagnosed hypertension
* Known high-risk pregnancy
* Diagnosed medical illness including diabetes mellitus (Types 1 \& 2), chronic kidney disease or gastro-intestinal diseases or any illness known to interfere with calcium metabolism (e.g. sarcoidosis).
* Consumption of medications known to interfere with vitamin D metabolism
* Consumption of vitamin D (≥ 10 µg/day) or calcium (≥ 650 mg/d) supplements prior to randomization

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial
Brief Summary: 200 women with PPH will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) and group 2 will receive oxytocin 10 IU (Syntocinon®, Novartis, Switzerland). The investigators will not include a control group for ethical reasons.


Options:
A: Inclusion Criteria:

* pregnant with a fetus \>/=24 weeks gestational age
* non-emergent cesarean delivery
* postpartum hemorrhage deemed the result of uterine atony

Exclusion Criteria:

* non-English speaking patients requiring an interpreter
* any hypertensive disorder
* cardiovascular disease
* asthma
* refusal of transfused blood products
* coagulopathy or abnormal coagulation lab values
* hypersensitivity to methylergonovine maleate or 15-methyl prostaglandin
B: Inclusion Criteria:

* All participants had PPH defined as vaginal bleeding\>500 ml after vaginal delivery and uterine atony confirmed by abdominal palpation

Exclusion Criteria:

* gestational age\<37 weeks,
* genital tract trauma,
* coagulation defect,
* women with hypertension, preeclampsia, cardiac, renal or liver diseases, epilepsy
* known hypersensitivity to carbetocin or oxytocin.
C: Inclusion Criteria:

* women delivering with provider from participating primary health unit (PHU)
* willing and able to give informed consent
* vaginal delivery

Exclusion Criteria:

* women too advanced into active labor to provide informed consent
* known allergy to misoprostol and/or other prostaglandin
* women presenting with pregnancy complications, such as hypertension, suspected multiple pregnancy, previous caesarean section, suspected still birth, antepartum hemorrhage, previous complication in the third trimester (should be referred to higher level care for delivery)
D: Inclusion Criteria:

* Atonic PPH

Exclusion Criteria:

* Gestational age\<37 weeks
* Hypertension, cardiac disease or preeclampsia

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial .
Brief Summary: There is no evidence that patients receiving magnesium sulfate before birth are required to maintain the drug for 24 hours. Therefore the investigators will have a randomized clinical study in patients with severe preeclampsia who have been treated with impregnation of magnesium sulphate and at least eight hours have received the drug before birth. If the patient agrees and signs the consent is randomized to: 1-receive sulfate for 24 hours postpartum as usual or, 2- not receiving the postpartum magnesium sulfate or other anticonvulsant drugs. This study can be conducted in 12 maternity latin america.


Options:
A: Inclusion Criteria:

Severe hypertensive disorder receiving magnesium sulfate prophylaxis for less than 8 hours at birth.

Exclusion Criteria:

* Complications such as: HELLP syndrome, renal failure, eclampsia, retinal detachment, cerebral edema, pulmonary edema, hypertensive encephalopathy.
B: Inclusion Criteria:

* Pregnant women who are ages 18-45
* 32-42 weeks' pregnant
* Prescribed magnesium sulfate for preeclampsia
* BMI ≥35 kg/m2

Exclusion Criteria:

* Pregnant women \< 32 weeks' pregnant
* Women who are on dialysis
C: Inclusion Criteria:

Exhibit systolic blood pressure \> 160mm Hg OR a diastolic pressure \> 110 mm Hg (at two times over 30 minutes) (A single higher pressure could be accepted if the clinical team felt that magnesium sulfate therapy should be initiated without waiting 30 minutes).

Exhibit proteinuria \> 1+; Have not given birth, or be \<24h postpartum Be assessed by enrolling physician to benefit from magnesium sulfate therapy Agree to comply with study procedures Be \> 18 years of age Give informed consent for study participation

Exclusion Criteria:

Eclamptic or seizing at the time of enrollment Received magnesium sulfate therapy 24h prior to study enrollment Known serum creatinine \>1.2 mg/dL. (Subject may be enrolled prior to knowledge of serum creatinine but would be withdrawn if \>1.2 mg/dL in order to have a proper dose adjustment.
D: Inclusion Criteria:

* Severe preeclampsia or severe preeclampsia aggregated to chronic hypertension with \> 24 weeks of gestation treated with 4-6 grams of magnesium sulfate for impregnation with a minimum of 8 hours continuous of magnesium sulfate before delivery
* The study begins to terminate pregnancy

Exclusion Criteria:

* HELLP syndrome
* Eclampsia
* Renal insufficiency
* Diabetes mellitus
* Disease of collagen
* Heart disease

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy
Brief Summary: The purpose of this pilot study is to examine the feasibility of conducting a multi-site randomized controlled trial whose aim will be to evaluate the effectiveness of a Patient Decision Aid (PDA) for antidepressant use in pregnancy.


Options:
A: Inclusion Criteria:

* Opioid Use Disorder diagnosis and agreement to follow study procedures (including permission to share medical records and other administrative records)

Exclusion Criteria:

* Significant or unstable medical or psychiatric illness that may interfere with study participation
B: Inclusion criteria:

1. Are females aged \>18 years old, and
2. Are either planning a pregnancy OR are \<30 weeks gestation at enrollment, and
3. Have been offered to start or continue SSRI or SNRI anti-depressant medication as a treatment option for depression by their clinical provider at one of the study sites, and
4. Have moderate-to-high decisional conflict (score of \>25 on the Decisional Conflict Scale)

Exclusion criteria:

1. Have had alcohol or substance abuse or dependence in the previous 12 months, or
2. Have active suicidal ideation or psychosis, or
3. Are incapable of consenting to participation, or
4. Have any major obstetrical complications or fetal cardiac anomaly in the current or in a past pregnancy (as this changes the risk/benefit ratio discussion in regards to antidepressant use), or
5. Are unable to read or unable to speak or understand English and do not have someone that can read the PDA to them, or
6. Have a visual impairment that would prevent them from being able to view the website.
C: Inclusion Criteria:

At least three visits to the General Mental Health Clinic's BHIP team in prior year

Exclusion Criteria:

Chart evidence of dementia
D: Inclusion Criteria:

1. A young person between 11 and 16 years of age with an emotional/internalising disorder who is accessing CAMHS.
2. A parent/guardian of a young person between 11 and 16 years of age with an emotional/internalising disorder who is accessing CAMHS.
3. A clinician in a participating CAMHS site.
4. Only those providing consent will be included. Where potential participants are under 16 parents/legal guardians will also have to provide consent.

Exclusion Criteria:

1. Any individual who is not accessing a participating CAMHS site.
2. Given there are no additional resources for an interpreter, children or parents who are not comfortable with English may not be included
3. Young people under the age of 11, or over the age of 16 would not be included.
4. Parents/guardians of young people with SEN (special educational needs) will not be included
5. Those who do not consent.

Answer: B